Nkarta presents preclinical data exploring gene knockout strategies and combination agents with nk cell-based therapies at the 2023 aacr annual meeting

Improved adcc with adam17 gene knockout of nk or car nk cells, supporting adam17 ko use for clinical applications increased specific killing of cancer cells in vitro by the combination of nkx101 and cetuximab, supporting use for combination in solid tumors south san francisco, calif., april 17, 2023 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the 2023 american association of cancer research (aacr) annual meeting.
NKTX Ratings Summary
NKTX Quant Ranking